.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 5,843,961

« Back to Dashboard

Details for Patent: 5,843,961

Title: Method and composition for treating erectile dysfunction
Abstract:Lipophilic active substance composition and its use in a new method of treating erectile dysfunction by administration thereof, optionally together with a hydrophilic vehicle and optionally an antibacterial agent into the urethra.
Inventor(s): Kock; Nils G. (S-413 19 Goteborg, SE), Lycke; Gerhard (S-421 67 Vastra Frolunda, SE)
Assignee:
Filing Date:Jun 07, 1995
Application Number:08/484,546
Claims:1. A pharmaceutical composition for administration to the urethra of a male individual to produce penile erection, comprising an effective amount of a lipophilic active agent dispersed in a hydrophilic vehicle, wherein;

(a) the hydrophilic vehicle is suitable for urethral administration and effective to facilitate passage of the lipophilic active agent through the urethral membrane so that the active agent reaches the corpora cavernosa; and

(b) the lipophilic active agent comprises an .alpha..sub.1 -receptor blocking agent present in the composition at a concentration effective to produce penile erection following administration of the composition to the urethra of the male individual.

2. The composition of claim 1, wherein the lipophilic active agent is prazosin.

3. The composition of claim 1, wherein the hydrophilic vehicle is selected from the group consisting of fat-free creams, fat-free ointments and macrogols.

4. The composition of claim 2, wherein the hydrophlic vehicle comprises a fat-free cream.

5. The composition of claim 3, wherein the hydrophilic vehicle comprises a fat-free cream.

6. The composition of claim 2, wherein the hydrophilic vehicle comprises a fat-free ointment.

7. The composition of claim 3, wherein the hydrophilic vehicle comprises a fat-free ointment.

8. The composition of claim 2, wherein the hydrophilic vehicle comprises a macrogol.

9. The composition of claim 3, wherein the hydrophilic vehicle comprises a macrogol.

10. The composition of claim 1, further comprising an antibacterial agent.

11. The composition of claim 1, wherein the pharmaceutical composition further comprises a vasoactive prostaglandin.

12. The composition of claim 11, wherein the vasoactive prostaglandin is prostaglandin E.sub.1.

13. The composition of claim 11, wherein the vasoactive prostaglandin is prostaglandin E.sub.2.

14. A method for treating erectile dysfunction in a male individual, comprising administering to the urethra of the individual an effective amount of a pharmaceutical composition comprising a known and therapeutically effective dosage of a lipophilic active agent selected from the group consisting of .alpha..sub.1 -receptor blockers and combinations thereof, and a hydrophilic vehicle suitable for urethral administration and effective to facilitate passage of the lipophilic active agent through the urethral membrane so that the active agent reaches the corpora cavernosa and produces penile erection.

15. The method of claim 14, wherein the dosage of lipophilic active agent administered in step (b) is effective to produce penile erection following administration.

16. The method of claim 14, wherein the lipophilic active agent is prazosin.

17. The method of claim 14, wherein the hydrophilic vehicle is selected to facilitate passage of the lipophilic active agent through the urethral membrane.

18. The method of claim 14, wherein the hydrophilic vehicle comprises a fat-free cream.

19. The method of claim 17, wherein the hydrophilic vehicle comprises a fat-free cream.

20. The method of claim 14, wherein the hydrophilic vehicle comprises a fat-free ointment.

21. The method of claim 17, wherein the hydrophilic vehicle comprises a fat-free ointment.

22. The method of claim 14, wherein the hydrophilic vehicle comprises a macrogol.

23. The method of claim 17, wherein the hydrophilic vehicle comprises a macrogol.

24. The method of claim 14, wherein the pharmaceutical composition further comprises an antibacterial agent.

25. The method of claim 14, wherein the pharmaceutical composition further comprises a vasoactive prostaglandin.

26. The method of claim 25, wherein the vasoactive prostaglandin is prostaglandin E.sub.1.

27. The method of claim 25, wherein the vasoactive prostaglandin is prostaglandin E.sub.2.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc